Therefore, ADAM17 inhibitors may observe efficacy in rheumatoid arthritis and multiple sclerosis models, since ADAM17 has been demonstrated to reduce the production of soluble TNF-α and decrease inflammation (17). Here, ADAM17 is linked to multiple sclerosis.